Genetic Tech (GENE) Unit Updates on BREVAGen Assessment Test

April 15, 2013 12:13 PM EDT
Get Alerts GENE Hot Sheet
Trade GENE Now!
Join SI Premium – FREE
Phenogen Sciences, the U.S. subsidiary of Australia-based Genetic Technologies Limited (Nasdaq: GENE), recently presented study results demonstrating that BREVAGen™, a first-in-class, scientifically-validated predictive breast cancer risk assessment test, more accurately identifies a woman's chances of getting breast cancer than the Breast Cancer Risk Assessment Tool (BCRAT) alone, leading to increased patient compliance with performing regular self breast exams and annual screenings. The clinical study, Impact of Genomics on the Assessment and Management of Breast Cancer Risk in a Woman's Healthcare Clinic was performed at Personalized Women's Healthcare in Plano, TX and the findings were presented at the 23rd Annual National Interdisciplinary Breast Center Conference in Las Vegas, NV, March 23-27, 2013. Typically, the identification of patients who are at an elevated risk for sporadic (non-hereditary, non-familial) breast cancer is performed using the National Cancer Institute's (NCI) BCRAT. But recently, with the introduction of the BREVAGen test, a woman's risk for developing sporadic, estrogen-positive breast cancer is more accurately identified. BREVAGen examines a woman's clinical risk factors, such as their lifetime exposure to estrogen, combined with scientifically validated markers to determine each patient's personalized five-year and lifetime risk of developing breast cancer. 1 BREVAGen test results support current American Cancer Society (ACS), American Society of Clinical Oncology (ASCO) and The National Comprehensive Cancer Network (NCCN) guidelines for prevention and early detection of breast cancer.2,3 "Our practice has been using the BREVAGen test for over a year and it has helped us to make more informed decisions in how we monitor our patients who are at risk and develop personalized breast health plans," said Eric Jacoby, M.D. "We are pleased that the results of our report clearly demonstrate that genetic information provided by the BREVAGen test show significant reductions in the five year and lifetime intermediate risk groups, 35 percent and 23 percent respectively." Study Results

In the study of 197 women over the age of 35, 68 percent had a higher than the population average five year risk for developing breast cancer, as assessed by the NCI-BCRAT. Evidence suggests that patients who are close to the 1.66 percent ASCO threshold, where it is important that an accurate risk assessment is made, are those who may see an impact of the BREVAGen test. This intermediate risk group in the BREVAGen study, who categorically fell between 1.5 and 2.0 percent, saw their five-year risk reduced by 35 percent. In the case of the lifetime risk where the ACS classifies the threshold at 20 percent, BREVAGen provided a 23 percent reduction for the intermediate risk group. The study results are clearly aligned with the ASCO and ACS thresholds and showed that when adding genotypic information from the BREVAGen test to the BCRAT, there is a significant reclassification of individual risk. Alignment with the ASCO and ACS thresholds enables healthcare professionals to develop future health plans for their patients. How BREVAGen Works

The BREVAGen predictive risk test is administered in a physician's office using a simple, non-invasive "oral-swab". Following analysis in our CLIA-certified laboratory, physicians receive a comprehensive genetic risk prediction report to review with the patient. The patient's risk of breast cancer is calculated by combining their relative risk score from seven genetic markers, called SNP's (single nucleotide polymorphisms), with factors that comprise the patient's clinical and reproductive history including current age, age at menarche, age at live first birth and race/ethnicity. The BREVAGen test provides five-year and lifetime predictive risk assessments to more accurately evaluate the patient's risk of developing sporadic breast cancer, regardless of family history. Clinically Validated

BREVAGen was proven superior in determining breast cancer risk compared to Gail score alone.1 BREVAGen is the first genetic risk prediction test to have been validated in a large scale, peer reviewed, case controlled study. Utilizing data from the U.S. Women's Health Initiative (WHI) Clinical Trial, 3,300 women underwent breast cancer assessment utilizing the BREVAGen test. Of those 3,300 women, 1,664 were diagnosed with breast cancer and 1,636 were in the breast cancer-free control group. About Breast Cancer

• Approximately one in eight women will get breast cancer equating to approx. 207,000 American women.4 • Up to 80% of women who get breast cancer do not have a strong family history of the disease.2 • Risk of invasive vs. non-invasive breast cancer is approximately four times greater in women age 40-645 • Approximately 75% of all breast cancer is estrogen-receptor positive and, if detected early, can be effectively treated with five-year survival rates of over 95% Breast Cancer Demographics.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Trading Halts

Add Your Comment